依达拉奉应用于进展性缺血性脑卒中患者的疗效及对血浆红细胞生成素的影响

Efficacy of edaravone in patients with progressive ischemic stroke and its effect on plasma erythropoietin

目的探讨依达拉奉应用于进展性缺血性脑卒中患者的疗效观察及对血浆红细胞生成素(EPO)的影响。方法选择我院收治的进展性缺血性脑卒中患者72例,以随机数字表将其分为研究组与对照组,每组36例。在常规对症支持治疗的基础上,研究组静滴依达拉奉治疗,对照组应用等容积的安慰剂生理盐水静滴。观察两组患者的临床疗效、治疗前、后血浆EPO水平及药物不良反应。结果研究组患者的临床治疗总有效率为88.89%,显著高于对照组的69.44%(P<0.05)。两组患者治疗前血浆EPO水平比较,差异无统计学意义(P>0.05);研究组患者治疗14 d时血浆EPO水平显著高于对照组与治疗前(P<0.05)。两组患者治疗期间均未发现明显的药物不良反应。结论依达拉奉应用于进展性缺血性脑卒中患者中疗效显著,可有效改善患者的神经功能状态,提高血浆EPO水平,适于临床推广。

Objective To investigate the efficacy of edaravone in patients with progressive ischemic stroke and its effect on plasma erythropoietin （EPO）. Methods A total of 72 cases of patients with progressive ischemic stroke in our hospital were divided into study group and the control group by random number table, with 36 cases in each group. On the basis of conventional symptomatic supportive therapy, the study group was treated with intravenous infusion of edaravone, and the control group received a constant volume of placebo saline intravenous infusion. The clinical efficacy, plasma EPO level and adverse drug reactions of the two group were observed before and after treatment. Results The total effective rate of the study group was 88.89%, which was significantly higher than 69.44% of the control group（P〈0.05）. There was no significant difference in plasma EPO levels between the two groups before treatment （P〉0.05）. The level of plasma EPO at 14 d in the study group was significantly higher than that in the control group and before treatment （P〈0.05）. There was no obvious adverse drug reactions in the two groups during the treatment. Conclusion Edaravone is effective in the treatment of patients with progressive ischemic stroke. It can effectively improve the neurological status and the level of plasma EPO, which is suitable for clinical promotion.